Current Report Filing (8-k)
09 3월 2023 - 6:06AM
Edgar (US Regulatory)
0001788028
false
0001788028
2023-03-08
2023-03-08
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2023-03-08
2023-03-08
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2023-03-08
2023-03-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 8, 2023
JASPER THERAPEUTICS,
INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39138 |
|
84-2984849 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
2200 Bridge Pkwy Suite #102
Redwood City, CA |
|
94065 |
(Address of principal executive offices) |
|
(Zip Code) |
(650) 549-1400
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange
on which registered |
Voting Common Stock, par value $0.0001 per share |
|
JSPR |
|
The Nasdaq Stock Market LLC |
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations
and Financial Condition.
On March 8, 2023, Jasper Therapeutics,
Inc. issued a press release reporting its financial results for the fiscal year ended December 31, 2022 and providing a business update.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instructions
B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished
under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section,
and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
JASPER THERAPEUTICS, INC.
|
|
|
|
Date: March 8, 2023 |
By: |
/s/ Jeet Mahal |
|
|
Name: |
Jeet Mahal |
|
|
Title: |
Chief Operating Officer and Chief Financial Officer |
2
Amplitude Healthcare Acq... (NASDAQ:AMHC)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Amplitude Healthcare Acq... (NASDAQ:AMHC)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Amplitude Healthcare Acquisition Corporation (나스닥)의 실시간 뉴스: 최근 기사 0
More Jasper Therapeutics, Inc. News Articles